Regeneron Pharmaceuticals Inc(REGN)

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

Snapshot
$616.09
52-Week Range
$503.25 – $821.11
YTD
-20.64%
IV Rank (30D)
4.76
Straddle Price
$43.00
P/C Vol Ratio
0.08
Market Cap
$64.2B
Fair Value
-11.2% vs price
Confidence: 100% Alpha Score: 0.11

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 0.5% and dividend payments are stable.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.53%
Beta vs SPY1.00
Cost of Equity (CAPM)9.44% (VRP-adj)
WACC9.26%
Volatility Risk Premium+1.1pp (IV − HV30), ERP adj -9bps
Effective Tax Rate14.2%
Rev. Growth (YoY, DCF input)-1.9%
DCF Horizon12 years explicit + fade
Free Cash Flow (TTM)$4.1B
Return on Equity (TTM)14.1%
Book / Price47.6% — banking bias active (P/B is primary)
Gross Margin (TTM)86.3%
FCF Margin (TTM)27.6%
Debt / Equity0.06
Quality Score4/6 — high quality (12y DCF)
Market-Implied Growth+3.2% (reverse-DCF on current price)
SMA 50$695.60 (Market Anchor value)
SMA 20 / Bollinger Mid$631.42
Bollinger Width / SMA202.8% (drives anchor stability)
Net Debt$-1.0B
Market Cap$66B
Peers used for multiples: ABT, PFE, TEVA (SIC-code peers; ETF co-membership was sector-incoherent)
Blended Fair Value
$543.50
Current Price
$612.14
Deviation
-11.2%
Forward-Return Rank SHORT gates ✓
?
Horizon Expected α z Pred Blended z Rank % Active?
21d -3.4% -0.14 -0.59 61.1%
42d -8.7% -1.01 -0.59 61.1%
63d -13.3% -1.57 -0.59 61.1%
Expected α = forward-return point estimate vs SPY (e.g., +7.5% means the predictor expects this stock to outperform SPY by 7.5% over that horizon). For SHORT direction the model uses a different ranking metric (conviction-weighted deviation, not the LGBM prediction); Expected α is shown for reference. flags rows where Expected α disagrees with the FV direction — two independent signals are in conflict; conviction is low even if rank looks extreme.
Forward-Return Rank. A proprietary ensemble of a machine-learning forward-return model and a conviction-weighted fundamental score, ranked cross-sectionally each day across the S&P 500 (and broader universes on the screener). Each stock is scored at three horizons (21/42/63 trading days). "Active" = top/bottom 5% AND all risk filters pass. Backtested mean alpha vs SPY on active picks: 21d LONG +13.4%, 63d +34.9% (S&P 500, walk-forward). Past performance is not indicative of future results.
Value vs momentum conflict ⚠. The "FV direction" (long/short) comes from the fundamentals-based engine — price vs intrinsic value. The "Expected α" comes from a separate machine-learning predictor trained on ~12 features (sector, options-implied move, beta, institutional flow, etc.). Sometimes the two disagree: a stock is overvalued by fundamentals but the predictor expects it to keep outperforming (sector or momentum tailwinds). When all 3 horizons disagree, treat the direction signal as low-conviction — neither model is strongly recommending a position.
MethodImplied PriceWeightDetail
DCF $445.22 17%
DDM (Gordon) $31.47 13%
Peer P/E $1015.99 5% median 24.8× · 3 peers
Peer EV/EBITDA $410.22 5% median 10.4× · 3 peers
Peer P/B $866.86 5% median 3.0× · 3 peers
Peer P/S $317.66 5% median 2.3× · 3 peers
Market Anchor (SMA50) $695.60 33% stability 100% (BB-width)
Options Expected (B-L 30d) $616.21 17% 45 strikes · skew -0.13
As of 2026-06-12 · updated 2026-06-12 20:59:55.687000
Info
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834)
Exchange
XNAS
Market Cap
$64.2B

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

Price History
Seasonality
MonthAvg ReturnYears of Data
Jan +0.45% 23
Feb +0.77% 23
Mar +2.55% 23
Apr +0.62% 23
May +1.81% 23
Jun -1.41% 23
Jul +6.88% 22
Aug +2.70% 22
Sep -0.12% 23
Oct +0.10% 23
Nov +4.00% 23
Dec +4.39% 23
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators
SMA 20: $626.38
SMA 50: $692.30
SMA 200: $696.46
Current: $612.14
EMA 12: $620.08
EMA 26: $643.80
MACD: -23.7261 | Signal: 2.3097
BEARISH
ADX (14): 38.32
TREND
+DI: 14.66
−DI: 32.94
Momentum Oscillators
RSI (14): 37.75
NEUTRAL
Stoch %K: 29.48
Stoch %D: 30.46
Williams %R: -63.81
Volume & Volatility
BB Upper: $669.06
BB Lower: $583.70
NEUTRAL
OBV: -26,443,657
Vol SMA 20: 1,237,830
Vol ROC: -67.19%
ATR: $18.76
True Range: $11.53
HV 20: 45.2%
HV 30: 39.1%
HV 60: 34.7%

Data Summary
Data Points: 500
Last Updated: 2026-06-13T13:41:38.509000
Date Range: 2024-06-14T00:00:00 – 2026-06-12T00:00:00
AI Analysis

Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.

Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.

Earnings History
6 of 8 under expected move
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2024-08-01 Pre-Market 4.83% 1.29% 0.27x Within
2024-10-31 After-Close 2.21% 0.52% 0.24x Within
2025-01-13 After-Close 4.74% 3.25% 0.69x Within
2025-04-29 Pre-Market 6.20% 6.54% 1.05x Exceeded
2025-08-01 Pre-Market 5.57% 1.98% 0.36x Within
2025-10-28 Pre-Market 5.41% 11.76% 2.17x Exceeded
2026-01-30 Pre-Market 5.67% 1.32% 0.23x Within
2026-04-29 Pre-Market 7.11% 6.21% 0.87x Within
Options Activity
IV Rank (30D)
4.76
IV Rank (7D)
24.41
Avg IV
49.1%
Straddle (30D)
$43.00
Straddle (7D)
$21.05
P/C Volume
0.08
Spread Scanner GPU

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Volatility Surface

Enter a ticker to render the implied volatility surface.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Beta (1Y vs SPY)
0.50
Correlation (SPY)
18.8%
0.04
Ann. Volatility
32.8%
SPY Volatility
12.3%

Low volatility - stock moves less than market

Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-03-31
Diluted shares outstanding: 108,025,000 (as of 2026-03-31)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

1,432 filers88,370,437 shares$65.06B value81.81% of float
# Filer Shares Value % of Total % of Float Period
1 VANGUARD GROUP INC Custodian 9,075,153 $7.00B 10.77% 8.40% 2025-12-31
2 BlackRock, Inc. Custodian 8,947,735 $6.91B 10.63% 8.28% 2026-03-31
3 STATE STREET CORP 4,664,478 $3.60B 5.54% 4.32% 2026-03-31
4 DODGE & COX 4,458,238 $3.44B 5.29% 4.13% 2026-03-31
5 JPMORGAN CHASE & CO Custodian 4,311,806 $3.23B 4.97% 3.99% 2026-03-31
6 FRANKLIN RESOURCES INC Custodian 2,722,071 $2.10B 3.23% 2.52% 2026-03-31
7 GEODE CAPITAL MANAGEMENT, LLC Custodian 2,607,732 $2.01B 3.09% 2.41% 2026-03-31
8 Nuveen, LLC Custodian 2,065,064 $1.60B 2.45% 1.91% 2026-03-31
9 LOOMIS SAYLES & CO L P 1,912,310 $1.48B 2.27% 1.77% 2026-03-31
10 WELLINGTON MANAGEMENT GROUP LLP Custodian 1,837,459 $1.42B 2.18% 1.70% 2026-03-31
11 Invesco Ltd. Custodian 1,724,478 $1.33B 2.05% 1.60% 2026-03-31
12 FMR LLC Custodian 1,518,192 $1.17B 1.80% 1.41% 2026-03-31
13 Capital World Investors 1,419,000 $1.10B 1.69% 1.31% 2026-03-31
14 MORGAN STANLEY Custodian 1,389,323 $1.07B 1.65% 1.29% 2025-12-31
15 GOLDMAN SACHS GROUP INC Custodian 1,300,558 $1.00B 1.54% 1.20% 2026-03-31
16 AQR CAPITAL MANAGEMENT LLC Custodian 1,231,008 $946.01M 1.45% 1.14% 2026-03-31
17 BANK OF AMERICA CORP /DE/ Custodian 1,189,584 $919.12M 1.41% 1.10% 2026-03-31
18 Amundi Custodian 1,009,798 $780.21M 1.20% 0.93% 2026-03-31
19 NORTHERN TRUST CORP Custodian 941,941 $727.78M 1.12% 0.87% 2026-03-31
20 TWO SIGMA INVESTMENTS, LP 812,236 $627.57M 0.96% 0.75% 2026-03-31
21 CHARLES SCHWAB INVESTMENT MANAGEMENT INC 804,508 $621.60M 0.96% 0.74% 2026-03-31
22 Bank of New York Mellon Corp Custodian 765,411 $591.39M 0.91% 0.71% 2026-03-31
23 Legal & General Group Plc Custodian 732,054 $565.61M 0.87% 0.68% 2026-03-31
24 UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME Custodian 723,621 $559.10M 0.86% 0.67% 2026-03-31
25 DEUTSCHE BANK AG\ Custodian 625,388 $483.20M 0.74% 0.58% 2026-03-31
41 filers$1.07B notional
# Filer Notional Value % of Total Period
1 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $259.38M 24.14% 2026-03-31
2 CITADEL ADVISORS LLC Custodian $165.11M 15.37% 2026-03-31
3 GOLDMAN SACHS GROUP INC Custodian $144.95M 13.49% 2026-03-31
4 JANE STREET GROUP, LLC Custodian $124.78M 11.61% 2026-03-31
5 IMC-Chicago, LLC Custodian $110.18M 10.26% 2026-03-31
6 Bronte Capital Management Pty Ltd. $52.95M 4.93% 2026-03-31
7 WOLVERINE TRADING, LLC Custodian $45.93M 4.27% 2025-09-30
8 Nantahala Capital Management, LLC $30.91M 2.88% 2026-03-31
9 MILLENNIUM MANAGEMENT LLC Custodian $21.79M 2.03% 2026-03-31
10 ROYAL BANK OF CANADA Custodian $13.60M 1.27% 2026-03-31
11 SIMPLEX TRADING, LLC Custodian $12.75M 1.19% 2026-03-31
12 GROUP ONE TRADING LLC Custodian $11.67M 1.09% 2026-03-31
13 SIG BROKERAGE, LP $11.59M 1.08% 2026-03-31
14 Squarepoint Ops LLC $8.42M 0.78% 2026-03-31
15 JPMORGAN CHASE & CO Custodian $7.49M 0.70% 2026-03-31
16 UBS Group AG Custodian $7.26M 0.68% 2026-03-31
17 Qube Research & Technologies Ltd $6.49M 0.60% 2026-03-31
18 Cubist Systematic Strategies, LLC $4.84M 0.45% 2025-09-30
19 PEAK6 LLC $4.71M 0.44% 2026-03-31
20 Alphadyne Asset Management LP $4.56M 0.42% 2026-03-31
21 Walleye Trading LLC $3.79M 0.35% 2026-03-31
22 BNP PARIBAS FINANCIAL MARKETS Custodian $3.63M 0.34% 2026-03-31
23 Point72 Asset Management, L.P. $3.55M 0.33% 2026-03-31
24 Allianz Asset Management GmbH $3.01M 0.28% 2026-03-31
25 NOMURA HOLDINGS INC $1.55M 0.14% 2026-03-31
37 filers$1.15B notional
# Filer Notional Value % of Total Period
1 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $469.61M 40.78% 2026-03-31
2 CITADEL ADVISORS LLC Custodian $133.20M 11.57% 2026-03-31
3 Point72 Asset Management, L.P. $111.11M 9.65% 2026-03-31
4 JANE STREET GROUP, LLC Custodian $87.85M 7.63% 2026-03-31
5 IMC-Chicago, LLC Custodian $76.18M 6.62% 2026-03-31
6 GROUP ONE TRADING LLC Custodian $37.32M 3.24% 2026-03-31
7 WOLVERINE TRADING, LLC Custodian $36.50M 3.17% 2025-09-30
8 MILLENNIUM MANAGEMENT LLC Custodian $31.91M 2.77% 2026-03-31
9 LMR Partners LLP $30.13M 2.62% 2026-03-31
10 SIMPLEX TRADING, LLC Custodian $16.61M 1.44% 2026-03-31
11 Eisler Capital Management Ltd. $16.08M 1.40% 2025-09-30
12 GOLDMAN SACHS GROUP INC Custodian $12.75M 1.11% 2026-03-31
13 JPMORGAN CHASE & CO Custodian $11.24M 0.98% 2026-03-31
14 HSBC HOLDINGS PLC Custodian $10.01M 0.87% 2026-03-31
15 UBS Group AG Custodian $9.74M 0.85% 2026-03-31
16 Squarepoint Ops LLC $7.11M 0.62% 2026-03-31
17 D. E. Shaw & Co., Inc. Custodian $6.03M 0.52% 2026-03-31
18 Alphadyne Asset Management LP $5.64M 0.49% 2026-03-31
19 Qube Research & Technologies Ltd $5.41M 0.47% 2026-03-31
20 Allianz Asset Management GmbH $5.18M 0.45% 2026-03-31
21 Verition Fund Management LLC $5.18M 0.45% 2026-03-31
22 Walleye Trading LLC $4.48M 0.39% 2026-03-31
23 CAPSTONE INVESTMENT ADVISORS, LLC $3.32M 0.29% 2026-03-31
24 BNP PARIBAS FINANCIAL MARKETS Custodian $3.09M 0.27% 2026-03-31
25 J. Goldman & Co LP $3.09M 0.27% 2026-03-31
Insider Activity
Latest: 2026-05-04
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-05-04 ARTHUR F RYAN Director Sell (S) −100 $705.24 -$70.5K EDGAR
2026-04-03 ARTHUR F RYAN Director Sell (S) −100 $777.27 -$77.7K EDGAR
2026-03-03 ARTHUR F RYAN Director Sell (S) −100 $785.50 -$78.5K EDGAR
2026-02-23 Huda Y Zoghbi Director Mixed $579.01 -$662.8K EDGAR
2026-02-11 ARTHUR F RYAN Director Sell (S) −100 $778.53 -$77.9K EDGAR
2026-02-11 Jason Pitofsky SVP Controller Mixed −1,036 $684.14 -$1.09M EDGAR
2026-01-08 Bonnie L Bassler Director Mixed $587.06 -$638.8K EDGAR
2026-01-06 CHRISTINE A POON Director Award (A) +155 EDGAR
2026-01-06 Bonnie L Bassler Director Award (A) +155 EDGAR
2026-01-06 MICHAEL S BROWN Director Award (A) +155 EDGAR
2026-01-06 N ANTHONY COLES Director Award (A) +155 EDGAR
2026-01-06 ARTHUR F RYAN Director Award (A) +155 EDGAR
2026-01-06 JOSEPH L GOLDSTEIN Director Award (A) +155 EDGAR
2026-01-06 David P Schenkein Director Award (A) +155 EDGAR
2026-01-06 Kathryn Guarini Director Award (A) +155 EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
37 insiders · @ $612.14
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Amerique du Nord S.N.C. Sanofi-Aventis 10%+ Owner 15,816,953 $9.68B $56.97M 1 2010-10-14
2 GEORGE YANCOPOULOS Bd. Co-Chair, President & CSO 510,460 $312.47M -$467.64M 57 2026-01-05
3 LEONARD S SCHLEIFER Bd. Co-Chair, President & CEO 370,577 $226.85M -$458.80M 50 2026-01-05
4 P ROY VAGELOS Director 336,039 $205.70M -$379.01M 75 2023-04-05
5 Sanofi 10%+ Owner 279,766 $171.26M -$9.52B 46 2020-06-11
6 MURRAY A GOLDBERG SVP Administration & Asst Secr 70,086 $42.90M -$56.70M 46 2014-12-18
7 NEIL STAHL EVP Research and Development 53,434 $32.71M -$151.48M 66 2024-12-18
8 ANDREW J MURPHY EVP Research 52,208 $31.96M -$57.65M 29 2025-12-11
9 Daniel P Van Plew EVP & General Mgr, Industrial 34,049 $20.84M -$135.29M 55 2025-12-11
10 GEORGE L SING Director 31,407 $19.23M -$146.52M 60 2026-01-06
11 JOSEPH J LAROSA EVP General Counsel and Secret 31,309 $19.17M -$42.93M 45 2025-12-09
12 Peter Powchik SVP Clinical Development & Reg 27,388 $16.77M -$40.97M 26 2016-12-19
13 Robert J Terifay EVP Commercial 26,913 $16.47M -$52.21M 30 2017-12-13
14 Robert E Landry EVP Finance CFO 23,963 $14.67M -$23.25M 60 2024-02-06
15 WILLIAM ROBERTS VP Reg Dev & Med Safety 21,844 $13.37M -$15.61M 26 2013-09-20
16 STUART KOLINSKI SVP General Counsel and Secret 20,039 $12.27M -$501.5K 7 2010-06-07
17 Michael S Aberman SVP Strategy Investor Relation 18,767 $11.49M -$16.86M 25 2017-06-23
18 Christopher R. Fenimore EVP Finance CFO 18,325 $11.22M -$30.33M 38 2025-12-09
19 ARTHUR F RYAN Director 17,503 $10.71M -$59.29M 80 2026-05-04
20 Marion McCourt EVP Commercial 14,546 $8.90M -$30.98M 60 2025-12-11
21 Douglas S McCorkle VP Controller and Asst Treasur 10,995 $6.73M -$28.03M 33 2015-12-29
22 ALFRED G GILMAN Director 10,612 $6.50M -$34.31M 26 2015-08-07
23 CHARLES A BAKER Director 9,000 $5.51M -$28.08M 29 2018-01-03
24 MICHAEL S BROWN Director 7,865 $4.81M -$73.07M 81 2026-01-06
25 ERIC M SHOOTER Director 7,000 $4.28M -$22.04M 22 2014-02-13
26 JOSEPH L GOLDSTEIN Director 6,703 $4.10M -$72.45M 96 2026-01-06
27 ROBERT ALEXANDER INGRAM Director 6,667 $4.08M -$708.0K 2 2015-05-27
28 CHRISTINE A POON Director 5,219 $3.19M -$70.40M 25 2026-01-06
29 Jason Pitofsky SVP Controller 4,712 $2.88M -$2.39M 6 2026-02-11
30 RANDALL RUPP SVP, Manufuring Operations 3,983 $2.44M -$781.1K 1 2007-04-17
31 Huda Y Zoghbi Director 3,341 $2.05M -$11.25M 18 2026-02-23
32 Marc Tessier-Lavigne Director 2,434 $1.49M -$54.63M 25 2023-01-05
33 N ANTHONY COLES Director 1,714 $1.05M -$20.62M 16 2026-01-06
34 Bonnie L Bassler Director 1,703 $1.04M -$22.33M 33 2026-01-08
35 Craig B. Thompson Director 775 $474.4K $0 5 2026-01-06
36 David P Schenkein Director 603 $369.1K $0 4 2026-01-06
37 Kathryn Guarini Director 603 $369.1K $0 4 2026-01-06
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
Recent SEC Filings
Latest: 2026-04-29
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Accession Link
2026-04-29 0000872589-26-000014 EDGAR
2026-04-08 0001104659-26-040661 EDGAR
2026-01-30 0000872589-26-000004 EDGAR
2026-01-12 0001104659-26-002691 EDGAR
2025-10-28 0000872589-25-000026 EDGAR
2025-10-06 0001104659-25-096921 EDGAR
2025-08-01 0000872589-25-000017 EDGAR
2025-06-18 0001104659-25-060637 EDGAR
2025-04-29 0001804220-25-000020 EDGAR
2025-02-04 0001804220-25-000007 EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
2026-02-04 0000872589-26-000008 EDGAR
2025-02-05 0001804220-25-000011 EDGAR
2024-02-05 0001804220-24-000009 EDGAR
2023-02-06 0001804220-23-000008 EDGAR
2022-02-07 0001804220-22-000007 EDGAR
2021-02-08 0001804220-21-000008 EDGAR
2020-02-07 0001532176-20-000008 EDGAR
2019-02-07 0001532176-19-000009 EDGAR
2018-02-08 0001532176-18-000013 EDGAR
2017-02-09 0001532176-17-000008 EDGAR
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-04-29 0000872589-26-000016 EDGAR
2025-10-28 0000872589-25-000028 EDGAR
2025-08-01 0000872589-25-000019 EDGAR
2025-04-29 0001804220-25-000022 EDGAR
2024-10-31 0001804220-24-000040 EDGAR
2024-08-01 0001804220-24-000028 EDGAR
2024-05-02 0001804220-24-000017 EDGAR
2023-11-02 0001804220-23-000031 EDGAR
2023-08-03 0001804220-23-000023 EDGAR
2023-05-04 0001804220-23-000016 EDGAR
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

P/E Ratio15.0
P/B Ratio2.0
P/S Ratio4.3
EV/EBITDA15.3
TTM Revenue$14.9B
TTM Net Income$4.4B
TTM EPS$41.05
ROE14.1%
Dividend Yield0.58%
Debt/Equity0.09